FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2805126793> ?p ?o ?g. }

• W2805126793 endingPage "AB326" @default.
• W2805126793 startingPage "AB326" @default.
• W2805126793 abstract "Occult dissemination of tumor cellular and nuclear material into the bloodstream is well-recognized and has been reported for a variety of tumor types, including pancreatic ductal adenocarcinoma (PDAC). These cells and nuclear material can be detected in the blood as circulating tumor cells (CTCs) or cell-free DNA (cfDNA) as a means of “liquid biopsy” and their presence is referred to as “tumoremia.” Limited data suggest that various biopsy procedures and surgery can also precipitate tumoremia. There are no published data indicating the risk of hematogenous tumor seeding following EUS FNA and no data clarifying whether any factors may be associated with its occurrence. In PDAC patients, we aimed to prospectively evaluate peripheral blood to determine the risk of EUS FNA-induced tumoremia and to identify the associated clinical, laboratory, and tumor demographic features. Peripheral blood from 35 patients with PDAC was collected before and following primary tumor EUS FNA. Plasma cfDNA concentrations and KRAS 12/13 mutation status were evaluated. Tumor seeding was defined by a ≥2-fold increase in cfDNA and/or conversion from circulating tumor deoxyribonucleic acid (ctDNA) KRAS mutant non-detectable to detectable. Factors that were evaluated to determine their correlation with tumoremia included age, gender, BMI, ECOG status, serum glucose level, CA 19-9 concentration, tumor location, tumor diameter, tumor stage, resectability status, number of FNA passes, infiltration of major arteries and veins, presence of IPMN, mortality, survival duration, pre-FNA cfDNA level, and the tumor allelic ratio. Based on our pre-defined metrics, either a ≥2-fold increase in the total cfDNA concentration (n=7; 20.6%), and/or conversion in ctDNA mutant detection status (n=3; 8.8%) primary tumor EUS FNA-induced hematogenous tumor seeding occurred in 10/35 (28.6%) patients. A broad spectrum of clinical, laboratory, and tumor demographic features were evaluated, none of which statistically correlated with a ≥2-fold increase in cfDNA, other than the number of major arteries and/or veins infiltrated by the primary tumor. (Table) The only feature that correlated with the conversion in KRAS mutation status was the CA 19-9 level. For the combined group (n=10), who met either metric for FNA-induced tumoremia, there were no characteristics that correlated with these endpoints. Our data indicate that the occurrence of hematogenous tumor seeding associated with EUS FNA at the present time, cannot be predicted based upon an evaluation of an extensive array of clinical, laboratory, and tumor related characteristics. Additional studies are needed to determine the clinical impact of EUS FNA-induced tumor seeding as well as to verify whether any predictive features can be identified to help predict its occurrence.Tabled 1≥2 fold increase in cfDNA concentrations &/or ctDNA- WT to ctDNA-MT Status (n=10)Remaining Cohort (n=25)P ValueAge (years)70.6 ± 6.269.4 ± 9.20.699Gender (female)4 (40.0%)14 (56.0%)0.471BMI24.8 ± 5.227.8 ± 6.90.229ECOG (≥1)1 (10.0%)9 (36.0%)0.407Glucose level (median; mg/dL)105.0 (98.0-107.0)121.5 (104.5-146.5)0.089Ca19-9 (median; U/mL)374.0 (222.0-1701.0)581.0 (74.5-1617.5)0.969Ca19-9 (>55 U/mL)9 (90.0%)19 (76.0%)0.645Tumor location (head)8 (80.0%)20 (80.0%)0.9Tumor diameter (long axis; mm)32.5 ± 6.531.9 ± 9.70.863Tumor diameter (short axis; mm)28.4 ± 7.026.4 ± 7.80.481Tumor stage (III/IV)5 (50.0%)11 (44.0%)0.9Tumor stage (I/II/III)8 (80.0%)18 (72.0%)0.9Tumor (resectable/borderline)5 (50.0%)14 (56.0%)0.9EUS FNA passes (median)5.5 (4.0-8.0)5.0 (4.8-6.0)0.739Infiltrate major artery (yes)4 (40.0%)11 (44.0%)0.9Infiltrate major vein (yes)4 (40.0%)15 (60.0%)0.454Infiltrate major artery or vein (yes)6 (60.0%)16 (64.0%)0.9# of major arteries/veins involved1.0 (0.0-2.0)2.0 (0.0-3.0)0.321Adenocarcinoma (non-IPMN)7 (70.0%)18 (72.0%)0.9Mortality (yes)6 (60.0%)14 (56.0%)0.9Time to mortality (median; months)6.4 (4-12.3)7.2 (4.4-11.3)0.9Perip Pre-FNA cfDNA level (ng/ml)0.6 (0.2-2.8)1.3 (0.6-3.5)0.201Allelic ratio (median; primary tumor)10.4 (1.5-23.4)18.9 (5.3-28.9)0.317 Open table in a new tab" @default.
• W2805126793 created "2018-06-13" @default.
• W2805126793 creator A5000992961 @default.
• W2805126793 creator A5009116026 @default.
• W2805126793 creator A5023410987 @default.
• W2805126793 creator A5027858713 @default.
• W2805126793 creator A5029126926 @default.
• W2805126793 creator A5037771197 @default.
• W2805126793 creator A5042657773 @default.
• W2805126793 creator A5070771967 @default.
• W2805126793 creator A5077228556 @default.
• W2805126793 creator A5079635965 @default.
• W2805126793 creator A5090319773 @default.
• W2805126793 date "2018-06-01" @default.
• W2805126793 modified "2023-09-24" @default.
• W2805126793 title "Su1371 PROSPECTIVE EVALUATION OF CLINICAL, LABORATORY, AND TUMOR-RELATED CHARACTERISTICS ASSOCIATED WITH HEMATOGENOUS TUMOR SEEDING FOLLOWING EUS FNA OF PANCREATIC DUCTAL ADENOCARCINOMA" @default.
• W2805126793 doi "https://doi.org/10.1016/j.gie.2018.04.1701" @default.
• W2805126793 hasPublicationYear "2018" @default.
• W2805126793 type Work @default.
• W2805126793 sameAs 2805126793 @default.
• W2805126793 citedByCount "0" @default.
• W2805126793 crossrefType "journal-article" @default.
• W2805126793 hasAuthorship W2805126793A5000992961 @default.
• W2805126793 hasAuthorship W2805126793A5009116026 @default.
• W2805126793 hasAuthorship W2805126793A5023410987 @default.
• W2805126793 hasAuthorship W2805126793A5027858713 @default.
• W2805126793 hasAuthorship W2805126793A5029126926 @default.
• W2805126793 hasAuthorship W2805126793A5037771197 @default.
• W2805126793 hasAuthorship W2805126793A5042657773 @default.
• W2805126793 hasAuthorship W2805126793A5070771967 @default.
• W2805126793 hasAuthorship W2805126793A5077228556 @default.
• W2805126793 hasAuthorship W2805126793A5079635965 @default.
• W2805126793 hasAuthorship W2805126793A5090319773 @default.
• W2805126793 hasBestOaLocation W28051267931 @default.
• W2805126793 hasConcept C121608353 @default.
• W2805126793 hasConcept C126322002 @default.
• W2805126793 hasConcept C142724271 @default.
• W2805126793 hasConcept C143998085 @default.
• W2805126793 hasConcept C188816634 @default.
• W2805126793 hasConcept C204787440 @default.
• W2805126793 hasConcept C2775934546 @default.
• W2805126793 hasConcept C2779013556 @default.
• W2805126793 hasConcept C2779529041 @default.
• W2805126793 hasConcept C2780283643 @default.
• W2805126793 hasConcept C2781182431 @default.
• W2805126793 hasConcept C2781187634 @default.
• W2805126793 hasConcept C520017518 @default.
• W2805126793 hasConcept C526805850 @default.
• W2805126793 hasConcept C61238886 @default.
• W2805126793 hasConcept C71924100 @default.
• W2805126793 hasConceptScore W2805126793C121608353 @default.
• W2805126793 hasConceptScore W2805126793C126322002 @default.
• W2805126793 hasConceptScore W2805126793C142724271 @default.
• W2805126793 hasConceptScore W2805126793C143998085 @default.
• W2805126793 hasConceptScore W2805126793C188816634 @default.
• W2805126793 hasConceptScore W2805126793C204787440 @default.
• W2805126793 hasConceptScore W2805126793C2775934546 @default.
• W2805126793 hasConceptScore W2805126793C2779013556 @default.
• W2805126793 hasConceptScore W2805126793C2779529041 @default.
• W2805126793 hasConceptScore W2805126793C2780283643 @default.
• W2805126793 hasConceptScore W2805126793C2781182431 @default.
• W2805126793 hasConceptScore W2805126793C2781187634 @default.
• W2805126793 hasConceptScore W2805126793C520017518 @default.
• W2805126793 hasConceptScore W2805126793C526805850 @default.
• W2805126793 hasConceptScore W2805126793C61238886 @default.
• W2805126793 hasConceptScore W2805126793C71924100 @default.
• W2805126793 hasIssue "6" @default.
• W2805126793 hasLocation W28051267931 @default.
• W2805126793 hasOpenAccess W2805126793 @default.
• W2805126793 hasPrimaryLocation W28051267931 @default.
• W2805126793 hasRelatedWork W1792294722 @default.
• W2805126793 hasRelatedWork W2079439893 @default.
• W2805126793 hasRelatedWork W2089646556 @default.
• W2805126793 hasRelatedWork W2145219115 @default.
• W2805126793 hasRelatedWork W2408995019 @default.
• W2805126793 hasRelatedWork W2416371593 @default.
• W2805126793 hasRelatedWork W2613124256 @default.
• W2805126793 hasRelatedWork W2613646596 @default.
• W2805126793 hasRelatedWork W2744057686 @default.
• W2805126793 hasRelatedWork W2885878117 @default.
• W2805126793 hasVolume "87" @default.
• W2805126793 isParatext "false" @default.
• W2805126793 isRetracted "false" @default.
• W2805126793 magId "2805126793" @default.
• W2805126793 workType "article" @default.